|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Probiotic metabolites from Bacillus coagulans GanedenBC30^(TM) support maturation of antigen-presenting cells in vitro显示文摘AIM:To study the effects of probiotic metabolites on maturation stage of antigen-presenting immune cells.METHODS:Ganeden Bacillus coagulans 30(GBC30) bacterial cultures in log phase were used to isolate the secreted metabolite(MET) fraction.A second fraction was made to generate a crude cell-wall-enriched fraction,by centrifugation and lysis,followed by washing.A preparation of MET was subjected to size exclusion centrifugation,generating three fractions:< 3 kDa,3-30 kDa,and 30-200 kDa and activities were tested in comparison to crude MET and cell wall in primary cultures of human peripheral blood mononuclear cell(PBMC) as a source of antigen-presenting mononuclear phagocytes.The maturation status of mononuclear phagocytes was evaluated by staining with monoclonal antibodies towards CD14,CD16,CD80 and CD86 and analyzed by flow cytometry.RESULTS:Treatment of PBMC with MET supported maturation of mononuclear phagocytes toward both macrophage and dendritic cell phenotypes.The biological activity unique to the metabolites included a reduction of CD14+ CD16+ pro-inflammatory cells,and this property was associated with the high molecular weight metabolite fraction.Changes were also seen for the dendritic cell maturation markers CD80 and CD86.On CD14dim cells,an increase in both CD80 and CD86 expression was seen,in contrast to a selective increase in CD86 expression on CD14bright cells.The co-expression of CD80 and CD86 indicates effective antigen presentation to T cells and support of T helper cell differentiation.The selective expression of CD86 in the absence of CD80 points to a role in generating T regulatory cells.CONCLUSION:The data show that a primary mechanism of action of GBC30 metabolites involves support of more mature phenotypes of antigen-presenting cells,important for immunological decision-making. | Kathleen F Benson Kimberlee A Redman Steve G Carter David Keller Sean Farmer John R Endres Gitte S Jensen | 2012 | World Journal of Gastroenterology2012，18，16： | 8 |
| 2 | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial显示文摘 | Eric Lawitz Fred F Poordad Phillip S Pang Robert H Hyland Xiao Ding Hongmei Mo William T Symonds John G McHutchison Fernando E Membreno | 2013 | The Lancet2013，，： | 5 |
| 3 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 4 | Palladium-cat-alyzed C-N(sp 2)Bond formation:N-Arylation of aromatic and un-saturration nitrogen and the reductive elimination chemistry of palladi-um azolyl nd methyleneamine complexes显示文摘 | Grace Mann John F Hartwig Michael S Drive | 1998 | J Am Chem Soc1998，，： | 2 |
| 5 | The heterodimeric structure of heterogeneous nuclear ribonucleoprotein C1/C2 dictates 1,25-dihydroxyvitamin D-directed transcriptional events in osteoblasts显示文摘Heterogeneous nuclear ribonucleoprotein(hnRNP) C plays a key role in RNA processing but also exerts a dominant negative effect on responses to 1,25-dihydroxyvitamin D(1,25(OH)2D) by functioning as a vitamin D response element-binding protein(VDRE-BP). hnRNPC acts a tetramer of hnRNPC1(huC1) and hnRNPC2(huC2), and organization of these subunits is critical to in vivo nucleic acid-binding. Overexpression of either huC1 or huC2 in human osteoblasts is sufficient to confer VDRE-BP suppression of 1,25(OH)2D-mediated transcription. However, huC1 or huC2 alone did not suppress 1,25(OH)2D-induced transcription in mouse osteoblastic cells. By contrast, overexpression of huC1 and huC2 in combination or transfection with a bone-specific polycistronic vector using a ‘‘self-cleaving'' 2A peptide to co-express huC1/C2 suppressed1,25D-mediated induction of osteoblast target gene expression. Structural diversity of hnRNPC between human/NWPs and mouse/rat/rabbit/dog was investigated by analysis of sequence variations within the hnRNP CLZ domain. The predicted loss of distal helical function in hnRNPC from lower species provides an explanation for the altered interaction between huC1/C2 and their mouse counterparts. These data provide new evidence of a role for hnRNPC1/C2 in 1,25(OH)2D-driven gene expression, and further suggest that species-specific tetramerization is a crucial determinant of its actions as a regulator of VDR-directed transactivation. | Thomas S Lisse Kanagasabai Vadivel S Paul Bajaj Rui Zhou Rene F Chun Martin Hewison John S Adams | 2014 | Bone Research2014，2，2： | 2 |
| 6 | 2004英国高血压学会高血压治疗指南(BHS-IV):概要显示文摘在高血压领域,不断出现的新证据已日益受到关注。例如:血压可作为心血管疾病的一个危险因素;改进生活方式对于预防和治疗高血压的重要意义;不同类型药物的有效性和安全性;高危高血压患者包括糖尿病患者的治疗;心血管疾病总体危险性评估的重要性以及使用他汀类药物所获得的额外益处。 | Bryan Williams Neil R Poulter Peter S Sever Morris J Brown Mark Davis Gordon T McInnes John F Potter 邱洪 | 2004 | 英国医学杂志中文版2004，7，5： | 2 |
| 7 | Functional polymers from novel carboxyl-terminated trithiocarbonates as highly efficient RAI agents 显示文摘 | John T L Debby F Rouald S | 2002 | Macromolecules2002，35，： | 1 |
| 8 | Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial显示文摘 | John R Teerlink Gad Cotter Beth A Davison G Michael Felker Gerasimos Filippatos Barry H Greenberg Piotr Ponikowski Elaine Unemori Adriaan A Voors Kirkwood F Adams Maria I Dorobantu Liliana R Grinfeld Guillaume Jondeau Alon Marmor Josep Masip Peter S Pang | 2013 | The Lancet . 2013 (9860)2013，，9860： | 1 |
| 9 | Transient expression and insertional mutagenesis of Puccinia triticina using biolistics显示文摘 | CRAIG A W LES J S GUUS B CLARKE G RICHARD C S MERLE E JOHN P F | 2005 | Functional & Integrative Genomics2005，12，： | 1 |
| 10 | Hemangiopericytoma of head and neck显示文摘 | John F C Bhuvanesh S Dennis H K | 1999 | Laryngoscope1999，109，9： | 1 |
| 11 | Techniques for the study and development of microbial fuel cells: an electrochemical perspective 显示文摘 | Zhao F Robert C T S John R V | 2009 | Chem Soc Rev2009，38，： | 1 |
| 12 | Use of surfactants to remove water-based inks from plastic film:effect of calcium ion concentration and length of surfactant hydrophobe显示文摘 | Hatice G John F S Sherril D C | 2004 | Colloid Polymer Science2004，283，： | 1 |
| 13 | Exploiting the virtual value chain显示文摘 | Jefrey F R John J S | 1995 | Harvard Business Review1995，73，6： | 1 |
| 14 | Dynamic monolayer behavior of a photo - responsive azobenzene surfactant 显示文摘 | INSUN K JOHN F R PIETER S | 2000 | Colloids and Surfaces A: Physicochemical and Engineering Aspects2000，171，： | 1 |
| 15 | Measuring micro-fibrillar angles using light microscopy 显示文摘 | JOHN F S BENDTSEN B A | 1980 | Wood Sci1980，17，4： | 1 |
| 16 | The operative management of pediatric fractures of the lower extremity显示文摘 | John M F David S Paul D | 2002 | J Bone Joint Surg Br2002，84，5： | 1 |
| 17 | Product customization and manufacturing strategy显示文摘 | MARTIN S JOHN F | 2000 | International Journal of Operations Production Management2000，20，4： | 1 |
| 18 | Leverage, growth and profitability as determinants of dividend payout ratio:evi- dence from Indian paper industry显示文摘 | JOHN S F MUTHUSAMY K | 2010 | Asian Journal of Business Management Studies2010，1，1： | 1 |
| 19 | HLA expression in cancer :Implication for T - cell based immunotherary 显示文摘 | Alessandro S Ronert C John F | 2001 | Immuno Geneties2001，53，4： | 1 |
| 20 | Matrix and fiber influences on the cryogenic microcracking of carbon fiber/epoxy composites显示文摘 | John F Timmerman Matthew S Tillman Brian S Hayes et at | 2002 | Composites2002，33，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员